Biomedical Microdevices and Nanotechnology Laboratory, Department of Bioengineering, University of Texas at Dallas, Richardson, Texas.
Enlisense LLC, Allen, Texas.
Curr Protoc. 2021 Jun;1(6):e150. doi: 10.1002/cpz1.150.
Glycans (oligosaccharide chains attached to glycoproteins) are a promising class of biomarkers, found in body fluids such as serum, saliva, urine, etc., that can be used for the diagnosis of disease conditions. Subtle changes in glycans resulting from altered glycosylation machinery have been reported during various diseases, including carcinogenesis. In this article, we detail protocols for the rapid, label-free analysis of glycans using a previously developed highly sensitive and selective electrochemical impedance spectroscopy-based biosensing diagnostic platform called "NanoMonitor." The glycosensor operation is based on the specific affinity capture of the target glycans on the sensor surface by glycan-binding proteins known as lectins. This glycan-lectin binding activity modulates the impedance of the electrical double layer at the buffer-electrode interface. Protocols for the preparation of glycoprotein samples and glycosylation analysis using NanoMonitor and lectin-based ELISA are described here. The data obtained using these protocols show that NanoMonitor is capable of distinguishing between glycoform variants of the glycoprotein fetuin and glycoproteins derived from cultured human pancreatic cancer cells with high sensitivity (orders of magnitude higher than lectin-based ELISA) and selectivity. The results obtained indicate that NanoMonitor protocols can be further developed to enable use of NanoMonitor as a handheld electronic biosensor device for routine multiplexed detection of glycan biomarkers from clinical samples. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Preparing the NanoMonitor surface for glycan biosensing Support Protocol: Synthesis of glycoform variants of fetuin Basic Protocol 2: Performing Electrochemical Impedance Spectroscopy (EIS) for analyzing glycoprotein structures.
聚糖(连接到糖蛋白上的寡糖链)是一类很有前途的生物标志物,存在于血清、唾液、尿液等体液中,可用于疾病状况的诊断。在各种疾病中,包括癌变,已经报道了由于糖基化机制改变而导致的聚糖的细微变化。在本文中,我们详细介绍了使用先前开发的基于高灵敏度和选择性电化学阻抗谱的生物传感诊断平台“NanoMonitor”快速、无标记分析聚糖的方案。该糖传感器的操作基于糖结合蛋白(称为凝集素)在传感器表面上对目标聚糖的特异性亲和捕获。这种糖-凝集素结合活性调节缓冲-电极界面处的双电层的阻抗。本文描述了使用 NanoMonitor 和基于凝集素的 ELISA 进行糖蛋白样品制备和糖基化分析的方案。使用这些方案获得的数据表明,NanoMonitor 能够以高灵敏度(比基于凝集素的 ELISA 高几个数量级)和选择性区分糖蛋白胎球蛋白的糖型变体和来自培养的人胰腺癌细胞的糖蛋白。结果表明,NanoMonitor 方案可以进一步开发,以使得 NanoMonitor 能够作为手持式电子生物传感器设备,用于从临床样本中常规多重检测聚糖生物标志物。© 2021 Wiley Periodicals LLC. 基本方案 1:为糖生物传感准备 NanoMonitor 表面 支持方案:胎球蛋白糖型变体的合成 基本方案 2:进行电化学阻抗谱(EIS)分析糖蛋白结构。